Rosenstock J, Frias J, Jastreboff AM et al (2023) Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA
Aburel OM, Brescu L, Buriman DG, Merce AP, Bn AM, Borza C, Morno C, Sturza A, Muntean DM (2024) Methylene blue reduces monoamine oxidase expression and oxidative stress in human cardiovascular adipose tissue
Blood 136 , 12251240 (2020)
L-carnitine is required in all living cells for the transport of fatty acids from the cytosol into the mitochondria during the breakdown of lipids (or fats) for the generation of metabolic energy
In the recent trial, participants on the highest 36-milligram dose had about a 2 percent greater risk of a serious adverse event, compared with those given a placebo